Search
Arvinas Inc
ARVNAdd to Watchlist
8.230USD
+0.030+0.37%
Close 07-29 16:00（ET）Quotes delayed by 15 min
530.84MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-29The current earnings forecast score of Arvinas Inc is 7.40, ranking 295 out of 384 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 21.00 and a low of 6.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
14.786
Target Price
+79.87%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Arvinas Inc
ARVN
17
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Arvinas Inc's expected revenue for the next quarter?
Arvinas Inc's expected revenue is 32.54M.
What is Arvinas Inc's price target?
Analysts forecast that Arvinas Inc's price target is USD 14.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 6.00.
How have Arvinas IncARVN's recent earnings per share performed?
The market expectation was USD -0.90, while Arvinas IncARVN's earnings per share (EPS) for the previous quarter was USD -1.04. EPS for the next quarter is expected at USD -0.37.
What is the analyst rating for Arvinas Inc?
Based on the ratings of Arvinas Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.